ENDRA Life Sciences- Warrants (12/05/2022) Overview
Valuation check: NDRAW's P/E ratio is -0.71, below the Technology sector average of 27.8.
Get informed when a big investor buys or sells
+ Follow-0.71
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for NDRAW is -0.71. That is below the Technology sector average of 27.8. Investors often review this figure alongside ENDRA Life Sciences- Warrants (12/05/2022)'s historical trend and sector peers before judging valuation or financial health.
Against Technology companies, NDRAW currently prints -0.71 for P/E ratio, while the sector average sits near 27.8. That is roughly 102.6% below the sector mean. Large gaps often invite a closer look at ENDRA Life Sciences- Warrants (12/05/2022)'s growth, margins, and balance sheet.
A P/E ratio of -0.71 for ENDRA Life Sciences- Warrants (12/05/2022) is not 'good' or 'bad' on its own. Compare it with the peer average (27.8) and with NDRAW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting NDRAW's P/E ratio (-0.71), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack ENDRA Life Sciences- Warrants (12/05/2022)'s P/E ratio against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.
